Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fruquintinib + sintilimab
- Development stage
- Unknown
- Lead developer
- HUTCHMED
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Fruquintinib + sintilimab is a combination therapy consisting of two agents: fruquintinib, a highly selective oral small molecule inhibitor of vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3, and sintilimab, a fully human monoclonal antibody targeting programmed cell death protein 1 (PD-1). Fruquintinib inhibits tumor angiogenesis by blocking VEGFR-mediated signaling pathways essential for new blood vessel formation in tumors. Sintilimab enhances anti-tumor immune responses by inhibiting the PD-1 pathway, thereby restoring T-cell activity against cancer cells. The combination leverages the synergistic effects of targeted antiangiogenic therapy with immunotherapy to improve outcomes in patients with advanced cancers. It has received conditional approval in China for advanced endometrial cancer with mismatch repair proficient tumors after prior systemic therapy failure and has demonstrated efficacy as second-line treatment for locally advanced or metastatic renal cell carcinoma (RCC) in clinical trials[1][3][4].
- Brand names
- TYVYT + ELUNATE
- Other names
- sintilimab + mFFNsintilimab plus fruquintinib
02
Targets
VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR-1 (Vascular endothelial growth factor receptor 1)PDCD1 (Programmed cell death protein 1 receptor)VEGFR3 (Vascular endothelial growth factor receptor 3)
Beyond the preview
Go deeper on fruquintinib + sintilimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fruquintinib + sintilimab.